Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.

Liu Z., Alexander JL., Lin KW., VIP Study Investigators None., Ahmad T., Pollock KM., Powell N.

DOI

10.1053/j.gastro.2022.10.010

Type

Journal article

Journal

Gastroenterology

Publication Date

02/2023

Volume

164

Pages

300 - 303.e3

Keywords

Humans, Antibodies, Neutralizing, Antibodies, Viral, COVID-19, COVID-19 Vaccines, Infliximab, SARS-CoV-2, Janus Kinase Inhibitors

Permalink Original publication